GM-CSF-mediated impairment of liver to synthesize albumin, cholinesterase, and cholesterol.
Serum albumin, cholinesterase, and cholesterol were measured in ten patients with aplastic anemia and eight with myelodysplastic syndrome who received the administration of recombinant human GM-CSF. Serum albumin, cholinesterase, and cholesterol were significantly lowered by the administration of GM-CSF and recovered after the cessation of GM-CSF. These data suggest that GM-CSF impairs the biosynthesis of liver cells and that cholesterol-lowering activity of GM-CSF, which is previously reported, is due to the impairment of liver biosynthesis by GM-CSF.
Takahashi
M
M
First Department of Internal Medicine, Niigata University School of Medicine, Japan.
Nikkuni
K
K
Moriyama
Y
Y
Shibata
A
A
D000741:Anemia, Aplastic / Q000097:blood / Q000188:drug therapy; D002784:Cholesterol / Q000097:blood*; D002802:Cholinesterases / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012709:Serum Albumin / Q000032:analysis*
D011994:Recombinant Proteins; D012709:Serum Albumin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D002784:Cholesterol; D002802:Cholinesterases